Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Clear all
Completed Phase 3 Interventional Results available

A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain

NCT02081391
View directory record Official record
Conditions
Acute Pain
Interventions
Tapentadol oral solution 4 mg/mL, Tapentadol oral solution 20 mg/mL, Placebo
Drug · Other
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
1 Day to 18 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Little Rock, Arkansas • Stanford, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

NCT04886518
View directory record Official record
Conditions
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Interventions
Pitolisant Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 31, 2026, 7:41 PM EDT
Terminated Phase 4 Interventional Results available

Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects

NCT01582282
View directory record Official record
Conditions
Non-Insulin-dependent Diabetes Mellitus
Interventions
placebo, 3.4 g psyllium BID, 6.8g psyllium BID
Dietary Supplement
Lead sponsor
Procter and Gamble
Industry
Eligibility
36 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 1990
U.S. locations
2
States / cities
Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Oct 31, 2026, 7:41 PM EDT
Recruiting Phase 2 Interventional

Clazakizumab vs. Placebo - COVID-19 Infection

NCT04494724
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Clazakizumab, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers

NCT03513523
View directory record Official record
Conditions
Fatty Liver
Interventions
Group 1 NRPT, Group 2 NRPT, Group 3 Placebo
Dietary Supplement · Other
Lead sponsor
Elysium Health
Industry
Eligibility
18 Years to 70 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
Hialeah, Florida • Lake Worth, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 31, 2026, 7:41 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

NCT05819359
View directory record Official record
Conditions
Parkinson's Disease
Interventions
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Drug
Lead sponsor
Bial R&D Investments, S.A.
Industry
Eligibility
35 Years to 80 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

NCT05687279
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
RSVt Vaccine, Control Group
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 23 Months
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Norfolk, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 31, 2026, 7:41 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

An Exploratory, Randomized, Blinded, Placebo-Controlled Trial of Folic Acid and L-methylfolate in Parkinson's Disease

NCT00853879
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Folic Acid, Vitamin B6, Vitamin B12, B6, B12, L-methylfolate, B6, B12, Placebo
Dietary Supplement
Lead sponsor
Northwell Health
Other
Eligibility
30 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 31, 2026, 7:41 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Music Therapy for Pain Management for Minor Procedures in Neonates.

NCT04313179
View directory record Official record
Conditions
Pain
Interventions
Music therapy, Sucrose
Other
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
37 Weeks to 42 Weeks
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 3 Interventional

Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus

NCT00388479
View directory record Official record
Conditions
Ileus
Interventions
Alvimopan
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Exton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2015 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Staccato Prochlorperazine in Migraine (in Clinic)

NCT00610428
View directory record Official record
Conditions
Migraine Headache, With or Without Aura
Interventions
Staccato Placebo, Staccato Prochlorperazine 5 mg, Staccato Prochlorperazine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Mount Vernon, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 31, 2026, 7:41 PM EDT
Terminated Phase 3 Interventional Results available

Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus

NCT00571519
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
rivoglitazone HCl, placebo, pioglitazone HCl, pioglitazone HCl 45 mg, metformin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
18
States / cities
Huntsville, Alabama • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD

NCT03247530
View directory record Official record
Conditions
ADHD
Interventions
Placebo, 100mg SPN-812, 200mg SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Dothan, Alabama • Hialeah, Florida • Meridian, Idaho + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 31, 2026, 7:41 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 4 Interventional Results available

Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

NCT00176436
View directory record Official record
Conditions
Schizophrenia
Interventions
Diet support group, Group counseling and exercise
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation

NCT01989234
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
YKP10811, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
69
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Not applicable Interventional Results available

Sensory Stimulation to Enhance Hand Function Post Stroke

NCT02675764
View directory record Official record
Conditions
Stroke
Interventions
Vibration, Placebo (for vibration), therapy
Other · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

NCT06735209
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Assessment of Mechanisms of Improved Wound Healing

NCT00673309
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion study, Insulin High Dose, oxandrolone, Propranolol, Growth Hormone, Insulin Low Dose, IGF-1/IGFBP-3, Itraconazole, Growth Hormone and Propranolol, Oxandrolone and Propranolol, Placebo or Control
Procedure · Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 90 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 31, 2026, 7:41 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Probiotic Supplementation in Breastfed Newborn Infants

NCT02286999
View directory record Official record
Conditions
Atopic Dermatitis, Food Allergies
Interventions
B. infantis, Placebo
Drug
Lead sponsor
Emanual Maverakis, MD
Other
Eligibility
1 Day to 7 Days
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

NCT02365532
View directory record Official record
Conditions
Long QT Syndrome
Interventions
GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Efficacy of Single-Use of Peroxyl Mouthwash for Reducing Bacteria Saliva and Bioaerosol Contamination Phase 2

NCT04717063
View directory record Official record
Conditions
Healthy
Interventions
Peroxyl Oral Product, Placebo
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cervical Preparation Before Dilation and Evacuation

NCT01751087
View directory record Official record
Conditions
Abortion, Induced
Interventions
Mifepristone, misoprostol, Osmotic dilators, placebo
Other · Drug · Device
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 31, 2026, 7:41 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy

NCT01319487
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
2304 Eye Drops High Dose, 2304 Eye Drops Low Dose, Placebo Eye Drops
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Phoenix, Arizona • Fort Myers, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 31, 2026, 7:41 PM EDT